Search clinical trials for: PF-05221304, PK, Japanese, NASH, ACC inhibitor

Total 125826 results

Pfizer

Completed

A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults

Healthy

Japan
Pfizer

Completed

OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS

Healthy

United States
Pfizer

Completed

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

Non-Alcoholic Fatty Liver Disease (NAFLD)

United States
Pfizer

Completed

Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States, Belgium, Czechia, Slovakia
Pfizer

Completed

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Canada
Pfizer

Completed

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis With Liver Fibrosis

Hong Kong, United States, Taiwan, Puerto Rico, China, Canada, Korea, Republic of, Bulgaria, Japan, India, Poland, Slovakia
Pfizer

Completed

Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects

Healthy

United States
Pfizer

Completed

Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects

Normal Healthy

United States
Pfizer

Completed

Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects

Healthy

Belgium
Columbia University
Pfizer

Withdrawn

Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism

NASH (Nonalcoholic Steatohepatitis) | NAFLD (Nonalcoholic Fatty Liver Disease)
Pfizer

Completed

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Israel, Taiwan, Canada, Australia, Poland
Assiut University

Not yet recruiting

Intrapartum Ultrasonography in Evaluation of the Progress of Labor

Progress pf Labor
Children's Hospital of Philadelphia
National Library of Medicine (NLM)

Completed

Comprehensive Clinical Decision Support (CDS) for the Primary Care of Premature Infants (PreemieCDS)

Prematurity

United States
Prince of Songkla University

Active, not recruiting

Gastric Volume After Ingestion of Carbohydrate Drink vs Water in Obese Volunteers

Obesity | Gastric Emptying

Thailand
Olympus Biotech Corporation

Completed

The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study (TRANS-North)

Diabetic Foot Ulcer of Neuropathic Origin

Belgium, Germany, Poland, Croatia, Bulgaria, Denmark, Slovakia, Hungary, Netherlands, Sweden
MTI University

Unknown

Triceps Taping on Elbow Flexion Tightness in Extended Erb's Palsy

Deformity Flexion

Egypt
Karen-Lise Garm Spindler
Zealand University Hospital; Vejle Hospital

Recruiting

OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer (OPTIMISE)

Colorectal Cancer | Metastatic Cancer

Denmark
Samsung Medical Center

Unknown

Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)

Nonsmall Cell Lung Cancer

Korea, Republic of
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected

HIV-1 Infection | Pf Subclinical Parasitemia

Kenya, Malawi, Uganda
Pfizer

Completed

A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects

Healthy Females

United States
Pfizer

Completed

A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers

Phase 1

Belgium
Samsung Medical Center

Unknown

Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer

Nasopharyngeal Cancer

Korea, Republic of
Pfizer

Withdrawn

An Open-label, Two-period, Fixed-sequence Study to Evaluate Multiple-dose Itraconazole Effect on The Single-dose PK of PF-06372865 in Healthy Subjects

Healthy

United States
Seoul National University Hospital

Unknown

The Recovery Profiles After Robotic or Open Thyroidectomy

Postoperative Pain | Postoperative Sorethroat

Korea, Republic of
Seoul National University Hospital

Recruiting

Registry for Degenerative Spinal Disease (RDSD) (RDSD)

Surgery | Degeneration Spine

Korea, Republic of
Pfizer

Completed

A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

Dyslipidemia | Hypercholesterolemia

United States, Canada
Seoul National University Hospital

Unknown

Predictive Model for Postoperative Complications in Hemi-hip Arthroplasty

Arthroplasty | Complication | Risk Factor | Elderly Patient

Korea, Republic of
Pfizer

Not yet recruiting

A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.

Healthy Participants
HaEmek Medical Center, Israel

Unknown

Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients

Herpes Zoster

Israel
Chinese PLA General Hospital
Gansu Provincial Maternity and Child-Care Hospital

Unknown

Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Poorly Healed Wounds of Postoperative Incision

MSCs-PFs in Treating Poorly Healed Wounds of Postoperative Incision
Pfizer

Completed

A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults

Healthy Participants

Netherlands
Chung-Ang University Gwangmyeong Hospital

Not yet recruiting

Comparison of Remimazolam and Propofol Combination vs. Propofol in IOM

Neurologic Disorder
Pfizer

Completed

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

Healthy

United States
Pfizer

Completed

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

Healthy Volunteer

United States
Pfizer

Completed

Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations

Healthy Participants

United States
Pfizer

Completed

A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia

Metabolic Diseases | Dyslipidemias | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias

United States
Samsung Medical Center

Unknown

Chemotherapy With or Without Radiosurgery for Asymptomatic Oligo Brain Metastasis

Nonsmall Cell Lung Cancer

Korea, Republic of
Pfizer

Completed

Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

Hypercholesterolemia

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Breast Cancer | Solid Tumors

China, United States, Mexico, Bulgaria, Spain, Brazil, Czechia, Argentina, South Africa
University College Dublin

Completed

Video- Or Direct Laryngoscopy for Endotracheal Intubation in Newborns (VODE)

Intubation, Intratracheal | Infant, Newborn | Laryngoscopes

Ireland
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Pfizer

Completed

A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men

Healthy Participants

Netherlands
Pfizer

Completed

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

Healthy Participants

United States, Belgium
Pfizer

Completed

To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity

Healthy

United Kingdom
Pfizer

Withdrawn

A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals

Healthy
Pfizer

Completed

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Spain, Israel, Korea, Republic of, Russian Federation, Turkey, Czechia, Hungary, Italy, Poland, Bulgaria, Denmark, Germany, Serbia, Austria, Slovakia, Ukraine, Georgia, Romania
Pfizer

Completed

Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects

Hypercholesterolemia

Japan
Pfizer

Active, not recruiting

PF-07104091 as a Single Agent and in Combination Therapy

Breast Cancer | Small Cell Lung Cancer | Ovarian Cancer

United States, China, Japan, Mexico, Bulgaria, Argentina
Pfizer

Completed

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Plaque Psoriasis | Atopic Dermatitis

United States, Canada, United Kingdom, Japan
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

Crohn's Disease

United States, Spain, Lebanon, Australia, Russian Federation, Korea, Republic of, Tunisia, Italy, Poland, Belgium, Austria, Germany, Saudi Arabia, Czechia, Hungary, Switzerland, Turkey, Slovakia, Ukraine, Georgia, Bosnia and Herzegovina and more

3

Subscribe